Sunday, June 16, 2024

Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live Access

Must read



KANSAS CITY, Kan., April 30, 2024 (GLOBE NEWSWIRE) — Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that longstanding Cingulate investor and board member Peter J. Werth will join Cingulate Chairman and CEO Shane J. Schaffer in a live Benzinga All Access event on Friday May 3, 2024, at 12:10 p.m. EST.

Mr. Werth, Founder and CEO of ChemWerth Inc., will discuss his background as a successful pharmaceutical executive and entrepreneur, as well as his perspective on capital markets, the biotech industry, and his vision for Cingulate. Dr. Schaffer will provide a company overview and recap recent Cingulate clinical and business updates.

The event may be viewed live on Benzinga’s YouTube channel,  Benzinga All Access, and will also be available for viewing on Cingulate’s website at  cingulate.com/investors.

Who: Cingulate Investor & Board Member Peter J. Werth and Cingulate Chairman & CEO Shane J. SchafferWhat: Benzinga All Live AccessWhen: Friday, May 3, 2024, at 12:10 p.m. EST

About Cingulate ®Cingulate Inc. (NASDAQ: CING), is a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of attention deficit/hyperactivity disorder (ADHD), Cingulate is identifying and evaluating additional therapeutic areas where PTR technology may be employed to develop future product candidates, including to treat anxiety disorders.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or
remove ads
.

Cingulate is headquartered in Kansas City. For more information visit  Cingulate.com.

Forward-Looking Statements  This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include all statements, other than statements of historical fact, regarding our current views and assumptions with respect to future events regarding our business, including statements with respect to our plans, assumptions, expectations, beliefs and objectives with respect to product development, clinical studies, clinical and regulatory timelines, market opportunity, competitive position, business strategies, potential growth opportunities and other statements that are predictive in nature. These statements are generally identified by the use of such words as may, could, should, would, believe, anticipate, forecast, estimate, expect, intend, plan, continue, outlook, will, potential and similar statements of a future or forward-looking nature. Readers are cautioned that any forward-looking information provided by us or on our behalf is not a guarantee of future performance. Actual results may differ materially from those contained in these forward-looking statements as a result of various factors disclosed in our filings with the Securities and Exchange Commission (SEC), including the Risk Factors section of our Annual Report on Form 10-K filed with the SEC on April 1, 2024. All forward-looking statements speak only as of the date on which they are made, and we undertake no duty to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or
remove ads
.

Investor RelationsThomas DaltonVice President, Investor & Public Relations, CingulateTDalton@cingulate.com913-942-2301

Matt KrepsDarrow Associatesmkreps@darrowir.com214-597-8200



More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article